Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14799799 | 0.90 | SCN5A (0.44) | SCN5ASCN9ASCN10A | |
| SCHEMBL6535664 | 0.90 | SCN5A (0.44) | SCN5ASCN9ASCN10A | |
| SCHEMBL9754189 | 0.85 | SCN5A (0.47) | SCN5ASCN9ASCN10A | |
| SCHEMBL29997619 | 0.84 | THRA (0.40) | SCN5ASCN9ASCN10A | |
| SCHEMBL29998258 | 0.84 | ATM (0.45) | — | |
| SCHEMBL14816076 | 0.82 | SCN5A (0.45) | SCN5ASCN9ASCN10A | |
| SCHEMBL13448904 | 0.82 | SCN5A (0.48) | SCN5ASCN9ASCN10A | |
| SCHEMBL16330807 | 0.81 | SCN5A (0.52) | SCN5ASCN9ASCN10A | |
| SCHEMBL27709035 | 0.81 | POLM (0.49) | — | |
| SCHEMBL14815784 | 0.81 | SCN5A (0.44) | SCN5ASCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORP (US) | 2025-10-09 | — | — | US | disclosed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| EP-4288062-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | Epalex Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-20050002867-A1 | Buccal, polar and non-polar sprays containing propofol | NOVADEL PHARMA INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1318798-A4 | WATER-SOLUBLE PRODRUGS OF PROPOFOL FOR TREATMENT OF MIGRAINE | VYREX CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1075489-B1 | WATER-SOLUBLE PRODRUGS OF 2,6-DIISOPROPYLPHENOL ANALOGUES | VYREX CORP (US) | 2003-08-20 | — | — | EP | disclosed |
| EP-1318798-A1 | WATER-SOLUBLE PRODRUGS OF PROPOFOL FOR TREATMENT OF MIGRAINE | VYREX CORPORATION (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6362234-B1 | HEADACHES | VYREX CORPORATION | 2002-03-26 | — | — | US | disclosed |
| WO-2002013810-A1 | WATER-SOLUBLE PRODRUGS OF PROPOFOL FOR TREATMENT OF MIGRAINE | VYREX CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| US-6254853-B1 | DRUGS WITH CARRIERS | VYREX CORPORATION | 2001-07-03 | — | — | US | disclosed |
| EP-1075489-A2 | WATER-SOLUBLE PRO-DRUGS OF 2,6-DIISOPROPYLPHENOL ANALOGUES | VYREX CORPORATION (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999058555-A2 | WATER-SOLUBLE PRO-DRUGS OF 2,6-DIISOPROPYLPHENOL ANALOGUES | VYREX CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | SCN5A 9/4885SCN9A 417/4885SCN10A 112/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | SCN5A 4850/4885SCN9A 4797/4885SCN10A 4847/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | SCN5A 3851/4885SCN9A 2885/4885SCN10A 4023/4885 |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | SCN5A 9/4885SCN9A 417/4885SCN10A 112/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | SCN5A 9/4885SCN9A 417/4885SCN10A 112/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | SCN5A 3851/4885SCN9A 2885/4885SCN10A 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.